---
schema_version: "secwatch.filing_event.v1"
accession: "0001613103-22-000016"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2022-05-26T23:59:59+00:00"
generated_at: "2026-06-25T06:47:35.138157+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Medtronic posts FY22 rev +5%, Q4 adj EPS +2%; hikes dividend 8%, forms kidney JV with DaVita

## Summary
- FY22 revenue $31.686B, +5% reported and organic; Q4 revenue $8.1B, -1% reported, +1% organic.
- Q4 GAAP diluted EPS $1.10 (+10%), non-GAAP diluted EPS $1.52 (+2%); FY22 GAAP diluted EPS $3.73 (+40%).
- Quarterly dividend raised to $0.68 from $0.63 (+8%); annual $2.72; 45th consecutive year of increases.
- Medtronic and DaVita form equally-owned kidney device JV; Medtronic contributes RCS ($325M FY22 rev). DaVita pays up to $400M value. Close expected calendar 2023.
- FY23 guidance issued; no material adjusted EPS impact from JV in current or near-term fiscal years.

## SEC filing metadata
- accession: 0001613103-22-000016
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2022-05-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000161310322000016/0001613103-22-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000161310322000016/mdt-20220526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001613103-22-000016
- JSON: https://secwatch.observer/filing/0001613103-22-000016.json
- Plain text: https://secwatch.observer/filing/0001613103-22-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.